4.6 Article

Arenavirus Nucleoprotein Targets Interferon Regulatory Factor-Activating Kinase IKKε

期刊

JOURNAL OF VIROLOGY
卷 86, 期 15, 页码 7728-7738

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.00187-12

关键词

-

类别

资金

  1. VonTobel Foundation
  2. University of Lausanne
  3. NIH/NIAID [RO1 AI047140, RO1 AI077719, RO1 AI079665]
  4. NIH [RO1 AI077719, HHSN272201000055C]

向作者/读者索取更多资源

Arenaviruses perturb innate antiviral defense by blocking induction of type I interferon (IFN) production. Accordingly, the arenavirus nucleoprotein (NP) was shown to block activation and nuclear translocation of interferon regulatory factor 3 (IRF3) in response to virus infection. Here, we sought to identify cellular factors involved in innate antiviral signaling targeted by arenavirus NP. Consistent with previous studies, infection with the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) prevented phosphorylation of IRF3 in response to infection with Sendai virus, a strong inducer of the retinoic acid-inducible gene I (RIG-I)/mitochondrial antiviral signaling (MAVS) pathway of innate antiviral signaling. Using a combination of coimmunoprecipitation and confocal microscopy, we found that LCMV NP associates with the I kappa B kinase (IKK)-related kinase IKK epsilon but that, rather unexpectedly, LCMV NP did not bind to the closely related TANK-binding kinase 1 (TBK-1). The NP-IKK epsilon interaction was highly conserved among arenaviruses from different clades. In LCMV-infected cells, IKK epsilon colocalized with NP but not with MAVS located on the outer membrane of mitochondria. LCMV NP bound the kinase domain (KD) of IKK epsilon (IKBKE) and blocked its autocatalytic activity and its ability to phosphorylate IRF3, without undergoing phosphorylation. Together, our data identify IKK epsilon as a novel target of arenavirus NP. Engagement of NP seems to sequester IKK epsilon in an inactive complex. Considering the important functions of IKK epsilon in innate antiviral immunity and other cellular processes, the NP-IKK epsilon interaction likely plays a crucial role in arenavirus-host interaction.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Virology

Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review

Kin Israel Notarte, Israel Guerrero-Arguero, Jacqueline Veronica Velasco, Abbygail Therese Ver, Maria Helena Santos de Oliveira, Jesus Alfonso Catahay, Md Siddiqur Rahman Khan, Adriel Pastrana, Grzegorz Juszczyk, Jordi B. Torrelles, Giuseppe Lippi, Luis Martinez-Sobrido, Brandon Michael Henry

Summary: This review examines the decline in efficacy of mRNA vaccines for COVID-19 in preventing breakthrough infections due to diminishing humoral immunity over time. The study finds that the peak humoral response is reached 21-28 days after the second dose, after which antibody levels progressively decline at 4-6 months post-vaccination. Regardless of patient-related factors, antibody levels show a decline in both anti-receptor binding domain IgG and anti-spike IgG. The study highlights the need for more efficient vaccination strategies to combat waning immunity.

JOURNAL OF MEDICAL VIROLOGY (2022)

Article Microbiology

Vaccinia Virus Attenuation by Codon Deoptimization of the A24R Gene for Vaccine Development

Maria M. Lorenzo, Aitor Nogales, Kevin Chiem, Rafael Blasco, Luis Martinez-Sobrido

Summary: This study demonstrates that poxviruses can be effectively attenuated by synonymous codon deoptimization, providing a new approach for the development of attenuated vaccines for the treatment of poxvirus infection.

MICROBIOLOGY SPECTRUM (2022)

Article Microbiology

GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2

Rena A. Mizrahi, Wendy Y. Lin, Ashley Gras, Ariel R. Niedecken, Ellen K. Wagner, Sheila M. Keating, Nikita Ikon, Vishal A. Manickam, Michael A. Asensio, Jackson Leong, Angelica Medina-Cucurella, Emily Benzie, Kyle P. Carter, Yao Chiang, Robert C. Edgar, Renee Leong, Yoong Wearn Lim, Jan Fredrik Simons, Matthew J. Spindler, Kacy Stadtmiller, Nicholas Wayham, Dirk Buscher, Jose Vicente Terencio, Clara Di Germanio, Steven M. Chamow, Charles Olson, Paula A. Pino, Jun-Gyu Park, Amberlee Hicks, Chengjin Ye, Andreu Garcia-Vilanova, Luis Martinez-Sobrido, Jordi B. Torrelles, David S. Johnson, Adam S. Adler

Summary: This study successfully generated a first-in-class recombinant hyperimmune globulin therapeutic against SARS-CoV-2 using microfluidics, flow sorting, and a targeted integration cell line. The drug was manufactured consistently at the clinical scale and offers a new approach to treating infectious diseases by targeting multiple epitopes of the virus.

PATHOGENS (2022)

Article Biology

Modeling SARS-CoV-2 and influenza infections and antiviral treatments in human lung epithelial tissue equivalents

Hoda Zarkoob, Anna Allue-Guardia, Yu-Chi Chen, Andreu Garcia-Vilanova, Olive Jung, Steven Coon, Min Jae Song, Jun-Gyu Park, Fatai Oladunni, Jesse Miller, Yen-Ting Tung, Ivan Kosik, David Schultz, James Iben, Tianwei Li, Jiaqi Fu, Forbes D. Porter, Jonathan Yewdell, Luis Martinez-Sobrido, Sara Cherry, Jordi B. Torrelles, Marc Ferrer, Emily M. Lee

Summary: This study investigates the cellular responses to SARS-CoV-2 and influenza A virus infections using human alveolar and tracheobronchial epithelial ALI tissue models, and demonstrates the pharmacological validity of these models as antiviral drug screening assay platforms.

COMMUNICATIONS BIOLOGY (2022)

Article Virology

Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus

Zachary R. Sia, Kevin Chiem, Wei-Chiao Huang, Amal Seffouh, Amir Teimouri Dereshgi, Tara Hogan, Joaquin Ortega, Bruce A. Davidson, Luis Martinez-Sobrido, Jonathan F. Lovell

Summary: This study demonstrates that an adjuvant-containing nanoliposome antigen display system can effectively induce mucosal immune responses in the respiratory system, leading to the production of local and systemic antibodies, and protect mice from influenza virus challenge.

JOURNAL OF VIROLOGY (2022)

Article Virology

Molecular Analyses of Clinical Isolates and Recombinant SARS-CoV-2 Carrying B.1 and B.1.617.2 Spike Mutations Suggest a Potential Role of Non-Spike Mutations in Infection Kinetics

Andrei Veleanu, Maximilian A. Kelch, Chengjin Ye, Melanie Flohr, Alexander Wilhelm, Marek Widera, Luis Martinez-Sobrido, Sandra Ciesek, Tuna Toptan

Summary: Some SARS-CoV-2 variants are less susceptible to neutralization by post-vaccine sera and monoclonal antibodies, raising concerns about disease control. This study investigates the impact of spike and non-spike mutations on the virus life cycle. The results suggest that non-spike mutations may play a role in infection kinetics.

VIRUSES-BASEL (2022)

Article Chemistry, Multidisciplinary

Rapid Generation of Circulating and Mucosal Decoy Human ACE2 using mRNA Nanotherapeutics for the Potential Treatment of SARS-CoV-2

Jeonghwan Kim, Antony Jozic, Anindit Mukherjee, Dylan Nelson, Kevin Chiem, Md Siddiqur Rahman Khan, Jordi B. Torrelles, Luis Martinez-Sobrido, Gaurav Sahay

Summary: This study demonstrates that engineered mRNA encoding soluble hACE2 can be delivered to cells using lipid nanoparticles, leading to the production of hsACE2 proteins. The hsACE2 proteins bind to the viral spike protein, preventing viral entry and effectively inhibiting SARS-CoV-2 and its pseudoviruses from infecting host cells. This proof of principle study suggests that mRNA-based nanotherapeutics could be a potential treatment for COVID-19.

ADVANCED SCIENCE (2022)

Article Microbiology

Monitoring SARS-CoV-2 Infection Using a Double Reporter-Expressing Virus

Kevin Chiem, Jun-Gyu Park, Desarey Morales Vasquez, Richard K. Plemper, Jordi B. Torrelles, James J. Kobie, Mark R. Walter, Chengjin Ye, Luis Martinez-Sobrido

Summary: Despite the availability of vaccines and antivirals, the SARS-CoV-2 virus continues to cause the COVID-19 pandemic, affecting healthcare institutions worldwide. Previous studies have generated replicable forms of the virus that express fluorescent or luciferase reporter proteins to track viral infection in vitro and/or in vivo. However, the limitations of these approaches have prevented their use in specific assays or studies. In this study, researchers engineered a new form of the virus that expresses both fluorescent (mCherry) and luciferase (Nluc) reporter genes, allowing for better understanding of the virus's behavior in vitro and in vivo. This new model was successfully used to study viral infection and transmission in rodent models using in vivo imaging systems.

MICROBIOLOGY SPECTRUM (2022)

Article Immunology

Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models

Maria M. Lorenzo, Alejandro Marin-Lopez, Kevin Chiem, Luis Jimenez-Cabello, Irfan Ullah, Sergio Utrilla-Trigo, Eva Calvo-Pinilla, Gema Lorenzo, Sandra Moreno, Chengjin Ye, Jun-Gyu Park, Alejandro Matia, Alejandro Brun, Juana M. Sanchez-Puig, Aitor Nogales, Walther Mothes, Pradeep D. Uchil, Priti Kumar, Javier Ortego, Erol Fikrig, Luis Martinez-Sobrido, Rafael Blasco

Summary: The COVID-19 pandemic highlights the need for fast responses and reliable technologies for vaccine development. This study reports on the construction and preclinical testing of a recombinant MVA vaccine, with the MVA-Spf vaccine candidate showing higher levels of antibodies, a stronger T cell response, and a higher degree of protection.

VACCINES (2023)

Article Microbiology

Highly Cross-Reactive and Protective Influenza A Virus H3N2 Hemagglutinin- and Neuraminidase-Specific Human Monoclonal Antibodies

Michael Piepenbrink, Fatai Oladunni, Aitor Nogales, Ahmed M. Khalil, Theresa Fitzgerald, Madhubanti Basu, Christopher Fucile, David J. Topham, Alexander F. Rosenberg, Luis Martinez-Sobrido, James J. Kobie

Summary: Influenza A virus (IAV) infections pose a significant threat to public health due to the variable nature of the virus. This study shows that immunization with a seasonal inactivated influenza vaccine (IIV) can increase the levels of antibodies against H3N2 IAV, a strain known for its genetic drift. These antibodies have broad and potent antiviral activity and can protect against various H3N2 IAV strains. They also persist in the bone marrow, indicating their potential for long-term immunity. These findings contribute to the development of a universal influenza vaccine.

MICROBIOLOGY SPECTRUM (2023)

Article Microbiology

Identification of In Vitro Inhibitors of Monkeypox Replication

Kevin Chiem, Aitor Nogales, Maria Lorenzo, Desarey Morales Vasquez, Yan Xiang, Yogesh K. Gupta, Rafael Blasco, Juan Carlos de la Torre, Luis Martinez-Sobrido

Summary: Despite the eradication of smallpox, some orthopoxviruses, such as monkeypox virus (MPXV), remain important human pathogens. Vaccines for smallpox are effective against MPXV, but limited in access. Current antiviral treatments for MPXV are limited to two FDA-approved drugs. Therefore, there is an urgent need to discover novel antivirals for the treatment of MPXV and other potentially zoonotic orthopoxvirus infections. Here, we found 13 compounds that inhibit both VACV and MPXV, derived from two different libraries of compounds known to inhibit various RNA viruses.

MICROBIOLOGY SPECTRUM (2023)

Article Immunology

Antibodies, B Cell Responses and Immune Responses to SARS-CoV-2 Infections

Luis Martinez-Sobrido, James J. Kobie

ANTIBODIES (2023)

Article Infectious Diseases

Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability

Angela Huttner, Selidji Todagbe Agnandji, Olivier Engler, Jay W. Hooper, Steve Kwilas, Keersten Ricks, Tamara L. Clements, Hulda R. Jonsdottir, Sravya Sowdamini Nakka, Sylvia Rothenberger, Peter Kremsner, Roland Zust, Donata Medaglini, Tom Ottenhoff, Ali M. Harandi, Claire-Anne Siegrist

Summary: This study reports the 5-year persistence and avidity of antibodies produced by the live-attenuated recombinant vesicular stomatitis virus expressing the Zaire Ebolavirus glycoprotein. The findings suggest that antibody titres at 1 year can predict antibody persistence at 5 years. Additionally, while antibody titres remained stable, the duration of live-virus neutralizing antibodies was shorter.

CLINICAL MICROBIOLOGY AND INFECTION (2023)

Article Virology

Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody

Ahmed M. Khalil, Michael S. Piepenbrink, Ian Markham, Madhubanti Basu, Luis Martinez-Sobrido, James J. Kobie

Summary: IBV contributes significantly to morbidity and mortality, particularly in children, necessitating improvements in vaccines and treatments. A specific hMAb, 1092D4, has been found to have minimal dependence on Fc-effector functions for in vivo antiviral activity.

VIRUSES-BASEL (2023)

Review Immunology

Vaccination and Antiviral Treatment against Avian Influenza H5Nx Viruses: A Harbinger of Virus Control or Evolution

Ahlam Alasiri, Raya Soltane, Akram Hegazy, Ahmed Magdy Khalil, Sara H. Mahmoud, Ahmed A. Khalil, Luis Martinez-Sobrido, Ahmed Mostafa

Summary: Despite being widespread in wild birds and domestic poultry, human infections with highly pathogenic avian influenza H5Nx viruses have been limited since 1996. Few countries use vaccination as a control strategy, while most rely on culling infected flocks. China and Egypt are the major sites where vaccination has been employed, particularly for clade 2.3.4.4b H5N1 viruses. However, improper implementation of control strategies in Egypt has resulted in continuous outbreaks and virus evolution. Comprehensive surveillance in endemic areas is crucial to understand the public health risk of newly emerging immune-evasive or drug-resistant H5Nx variants.

VACCINES (2023)

暂无数据